The early inflammatory response to LCMV is counter balanced by a pronounced restorative response in Prf1^−/− mice treated with ruxolitinib. (A) Analysis of the relative (left) and absolute (right) number of each macrophage subset expressed as relative to mean total macrophage number in the liver of control (B6) and Prf1^−/− mice either nontreated or treated with ruxolitinib for 14 days at the indicated times. Data (mean ± SEM) are representative of 2 independent experiments with at least 3 mice in each group. *P < .05; ***P < .001; ****P < .0001). (B) Relative expression of Chil3 and Il10 in sorted hepatic macrophages obtained after LCMV infection from control (B6) and Prf1^−/− mice either nontreated or treated with ruxolitinib for 14 days, at the indicated times. Data (mean ± SEM) are representative of 2 independent experiments with at least 3 mice in each group. *P < .05; **P < .005.